Sensitization of Non-Small Cell Lung Cancer Cells to Gefitinib and Reversal of Epithelial–Mesenchymal Transition by Aloe-Emodin Via PI3K/Akt/TWIS1 Signal Blockage

Frontiers in Oncology

Lijun Zhang¹  Le Fang²  Xuewen Liu³  Minghui Peng³  Qingnan Tang³  Shaoyang Chen³  Zhuifeng Zheng⁴  Rongxiu Feng⁵ 

[1]Department of Oncology, Huaihua First People’s Hospital, Changde, China

[2]Department of Oncology, Loudi Central Hospital, Loudi, China

[3]Department of Oncology, Third Xiangya Hospital, Central South University, Changsha, China

[4]Department of Radiation Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China

[5]Department of Radiation Oncology, Xiangtan Central Hospital, Changde, China

关键词: aloe-emodin;    gefitinib;    NSCLC;    drug resistance;    EMT;   

DOI  :  10.3389/fonc.2022.908031

来源: DOAJ

【 摘 要 】

ObjectiveTo explore the impacts of AE (aloe-emodin) in gefitinib-resistant NSCLC (non-small cell lung cancer) cells and the corresponding mechanism.MethodsPC9 and PC9-GR cells were cultured and treated by gefitinib, AE, or the combination of the two drugs. Then, viability, apoptosis, migration and invasion of cells were investigated using CCK-8, TUNEL, wound healing assay, and transwell assay, respectively. Female BALB/c nude mice were employed for the establishment of xenograft tumor models to examine the role of AE in tumor growth.ResultsPC9-GR cells showed reduced apoptosis and enhanced cell viability, migration and invasion upon treatment by gefitinib, compared with PC9 cells. E-cahherin in PC9-GR cells was down-regulated, while Vimentin, Snail2 (or Slug) and Twist1 in PC9-GR cells were up-regulated, compared with PC9 cells. Meanwhile, treatment by a combination of gefitinib and AE significantly strengthened apoptosis of PC9-GR cells, while attenuated their migration and invasion, compared with the control group or treatment by gefitinib or AE alone. WB results showed that AE could reverse EMT and activation of PI3K/AKT signalling pathway in PC9-GR cells. In vivo experiments showed that tumor growth and EMT of PC9-GR cells were dramatically repressed after treatment by a combination of AE and gefitinib. Additionally, the use of SC97 (a PI3K/Akt pathway activator) could counteract the effects of AE in gefitinib-resistant PC9 cells.ConclusionsAE could enhance the gefitinib sensitivity of PC9-GR cells and reverse EMT by blocking PI3K/Akt/TWIS1 signal pathway.

【 授权许可】

Unknown